Clinical Trial Update: Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase II clinical trial evaluating pembrolizumab plus the GVD regimen as second-line therapy for relapsed or refractory Hodgkin lymphoma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Doxorubicin (doxorubicin)
• Gemcitabine (Gemcitabine)
• Pembrolizumab (pembrolizumab)
• Vinorelbine (Vinorelbine)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Hodgkin Lymphoma, Relapsed or Refractory Hodgkin Lymphoma | Phase 2 | Status: RECRUITING